Synapse

← Steven A. Rosenberg

Papers by Steven A. Rosenberg

Page 3 · newest first

  1. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6Clinical Cancer Research · 2015
  2. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytesJournal of Clinical Investigation · 2015
  3. Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic MelanomaMolecular Therapy · 2015
  4. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor ActivityJournal of Virology · 2015
  5. Adoptive cell transfer as personalized immunotherapy for human cancerScience · 2015
  6. Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T CellsJournal of Clinical Oncology · 2015
  7. Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic MelanomaClinical Cancer Research · 2015
  8. A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with ResponseClinical Cancer Research · 2014
  9. Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy Can Induce Remissions of Chemotherapy-Refractory Diffuse Large B-Cell LymphomaBlood · 2014
  10. Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell CharacteristicsCancer Research · 2014
  11. Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in HumansClinical Cancer Research · 2014
  12. Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With CancerJournal of Clinical Oncology · 2014
  13. T-Cell Immunotherapy: Looking ForwardMolecular Therapy · 2014
  14. Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen ReceptorJournal of Clinical Oncology · 2014
  15. Use of the piggyBac Transposon to Create Stable Packaging Cell Lines for the Production of Clinical-Grade Self-Inactivating γ-Retroviral VectorsHuman Gene Therapy Methods · 2014
  16. Specific Increase in Potency via Structure-Based Design of a TCRThe Journal of Immunology · 2014
  17. Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor RegressionsClinical Cancer Research · 2014
  18. IL-2: The First Effective Immunotherapy for Human CancerThe Journal of Immunology · 2014
  19. Rapid cell expansion (RACE) technology for production of engineered autologous T-cell therapy: Path toward manageable multicenter clinical trials in aggressive NHL with anti-CD19 CAR.Journal of Clinical Oncology · 2014
  20. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial CancerScience · 2014
  21. Aphasia As a Complication Of CD19-Targeted Chimeric Antigen Receptor Immunotherapy (S52.006)Neurology · 2014
  22. A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic CancerHuman Gene Therapy · 2014
  23. Melanoma NOS1 expression promotes dysfunctional IFN signalingJournal of Clinical Investigation · 2014
  24. Development of a T Cell Receptor Targeting an HLA-A*0201 Restricted Epitope from the Cancer-Testis Antigen SSX2 for Adoptive Immunotherapy of CancerPLoS ONE · 2014
  25. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumorsJournal of Clinical Investigation · 2014
  26. Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell InfiltrationClinical Cancer Research · 2014
  27. A Novel Murine T-Cell Receptor Targeting NY-ESO-1Journal of Immunotherapy · 2014
  28. Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiationCancer · 2014
  29. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cellsJournal for ImmunoTherapy of Cancer · 2014
  30. EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen LossClinical Cancer Research · 2013
  31. Exploiting the curative potential of adoptive T‐cell therapy for cancerImmunological Reviews · 2013
  32. Donor-Derived Anti-CD19 Chimeric-Antigen-Receptor-Expressing T Cells Cause Regression Of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell TransplantationBlood · 2013
  33. Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Blood · 2013
  34. Tumor-Reactive CD8+ T Cells in Metastatic Gastrointestinal Cancer Refractory to ChemotherapyClinical Cancer Research · 2013
  35. T cell receptor affinity and avidity defines antitumor response and autoimmunity in T cell immunotherapyJournal for ImmunoTherapy of Cancer · 2013
  36. 2 D TCR –p MHC – CD 8 kinetics determines T ‐cell responses in a self‐antigen‐specific TCR systemEuropean Journal of Immunology · 2013
  37. Structure-Based Design of Altered MHC Class II–Restricted Peptide Ligands with Heterogeneous ImmunogenicityThe Journal of Immunology · 2013
  38. Adoptive Cell Transfer for Patients with Metastatic Melanoma: The Potential and Promise of Cancer ImmunotherapyCancer Control · 2013
  39. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2British Journal of Cancer · 2013
  40. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantationBlood · 2013
  41. Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma ImmunotherapyClinical Cancer Research · 2013
  42. Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer TherapyThe Journal of Immunology · 2013
  43. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanomaProceedings of the National Academy of Sciences · 2013
  44. Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytesBlood · 2013
  45. Highlights of the society for immunotherapy of cancer (SITC) 27th annual meetingJournal for ImmunoTherapy of Cancer · 2013
  46. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexiaThe Journal of Experimental Medicine · 2013
  47. Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor RegressionThe Journal of Immunology · 2013
  48. Randomized Selection Design Trial Evaluating CD8⁺-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With MelanomaJournal of Clinical Oncology · 2013
  49. Simultaneous Targeting of Tumor Antigens and the Tumor Vasculature Using T Lymphocyte Transfer Synergize to Induce Regression of Established Tumors in MiceCancer Research · 2013
  50. Collapse of the Tumor Stroma is Triggered by IL-12 Induction of FasMolecular Therapy · 2013